Insulin Degludec
drugOn this page
Also known as Ins tresibaInsulina degludecInsuline degludecNN-1250NN1250Tresiba
Summary
Insulin Degludec (CHEMBL2107869) is an approved protein (ATC A10AE06); indicated across 3 conditions including diabetes mellitus and type 1 diabetes mellitus.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- ATC class: A10AE06
- Indications: 3 conditions
- Clinical trials: 196
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2107869 |
| Name | Insulin Degludec |
| Type | Protein |
| Max phase | 4 |
| ATC | A10AE06 |
Also known as: Ins tresiba, Insulin degludec, Insulina degludec, Insuline degludec, NN-1250, NN1250, Tresiba, INSULIN DEGLUDEC
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| diabetes mellitus | 4 | MONDO:0005015 | EFO:0000400 |
| type 1 diabetes mellitus | 3 | MONDO:0005147 | MONDO:0005147 |
| type 2 diabetes mellitus | 3 | MONDO:0005148 | MONDO:0005148 |
Clinical trials
Total trials: 196.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 79 |
| PHASE1 | 57 |
| Not specified | 25 |
| PHASE4 | 19 |
| PHASE2 | 14 |
| PHASE2/PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07173712 | PHASE4 | NOT_YET_RECRUITING | Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes |
| NCT02680457 | PHASE4 | COMPLETED | Effect of Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Patients With Type 2 Diabetes Mellitus |
| NCT02738151 | PHASE4 | COMPLETED | Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist |
| NCT02967211 | PHASE4 | COMPLETED | A Real World Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to Standard of Care Basal Insulin in Patients Already Using Basal Insulin |
| NCT02967224 | PHASE4 | COMPLETED | A Real World Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to Standard of Care Basal Insulins in Insulin Naïve Patients Initiating Insulin |
| NCT03244241 | PHASE4 | UNKNOWN | Basal-bolus Insulin Therapy Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study |
| NCT03328845 | PHASE4 | COMPLETED | Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study) |
| NCT03349840 | PHASE4 | TERMINATED | Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan |
| NCT03668808 | PHASE4 | COMPLETED | Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones. |
| NCT03687827 | PHASE4 | COMPLETED | A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study |
| NCT03838783 | PHASE4 | UNKNOWN | Flexible Insulin Therapy Untethered Insulin Regimen in Avidly Exercising Patients With Type 1 Diabetes: FIT Untethered |
| NCT04075513 | PHASE4 | COMPLETED | Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients |
| NCT04538352 | PHASE4 | COMPLETED | Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D |
| NCT04623086 | PHASE4 | COMPLETED | Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose |
| NCT05218915 | PHASE4 | COMPLETED | Basal Plus GLP1-ra on Glycemic Variability in CKD |
| NCT05243628 | PHASE4 | COMPLETED | Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes |
| NCT05360537 | PHASE4 | COMPLETED | Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients |
| NCT05552859 | PHASE4 | TERMINATED | Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment |
| NCT05904743 | PHASE4 | COMPLETED | INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes |
| NCT06559722 | PHASE3 | NOT_YET_RECRUITING | A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes |
| NCT06767748 | PHASE3 | ACTIVE_NOT_RECRUITING | A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin |
| NCT00972283 | PHASE3 | COMPLETED | Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes |
| NCT00978627 | PHASE3 | COMPLETED | Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes |
| NCT00982228 | PHASE3 | COMPLETED | Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes |
| NCT00982644 | PHASE3 | COMPLETED | Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes |
| NCT01006291 | PHASE3 | COMPLETED | Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes |
| NCT01009580 | PHASE3 | COMPLETED | Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes |
| NCT01045447 | PHASE3 | COMPLETED | Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes |
| NCT01045707 | PHASE3 | COMPLETED | Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes |
| NCT01046110 | PHASE3 | COMPLETED | Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin |
| NCT01059799 | PHASE3 | COMPLETED | Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes |
| NCT01059812 | PHASE3 | COMPLETED | A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes |
| NCT01068665 | PHASE3 | COMPLETED | Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes |
| NCT01068678 | PHASE3 | COMPLETED | Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes |
| NCT01074268 | PHASE3 | COMPLETED | Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes |
| NCT01076647 | PHASE3 | COMPLETED | Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes |
| NCT01079234 | PHASE3 | COMPLETED | Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes |
| NCT01135992 | PHASE3 | COMPLETED | Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™) |
| NCT01272193 | PHASE3 | COMPLETED | Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes |
| NCT01326026 | PHASE3 | COMPLETED | Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).